This program will showcase both drugs and devices under
development to treat the second leading cause of blindness globally.  You will
also gain valuable perspectives from clinical and industry leaders.

PROUDLY SPONSORED BY:

Allergan

Allergan (NYSE: AGN) is a unique, global pharmaceutical company focused on developing, manufacturing and commercializing high quality generic and innovative branded pharmaceutical products for patients around the world.  The Company has approximately 30,000 employees worldwide and maintains global headquarters in Dublin, Ireland.

Sanoculis

Sanoculis is developing and markets the MIMS (Minimally Invasive Micro Sclerostomy) device and technique for the treatment of the Glaucoma.
MIMS is simple, fast, and minimally invasive. During the procedure, a sclero-corneal drainage channel is created to reduce IOP. The novelty of the solution is that the channel ensures long-lasting controlled fluid flow with minor complications. MIMS consists of a disposable sterile tool and a multi-use external machine. Its expected benefits are: a stent-less procedure, low risk of complications, it is suitable for most Glaucoma patients, has the potential for medication reduction, can be easily combined with Cataract surgery and surgeon-friendly, automatic with short learning curve. MIMS is designed to reduce caring costs through procedure simplicity, low cost, fewer post-surgical complications and less hospitalization.

MEDIA PARTNER:

AGENDA | OCTOBER 15

1:00 – 1:10 PM

Welcome and Glaucoma Market Overview

1:10 – 2:06 PM

Company Showcase

2:06 – 2:45 PM

Glaucoma Outlook Panel

2:45 – 4:00 PM

Virtual Networking

GET INVOLVED

Learn how your company can get involved in another successful OIS meeting.

SPONSOR THIS EVENT

Gain valuable exposure and visibility for your company's branding.

APPLY TO PRESENT

Increase awareness of your technology & the
developmental stage of your company.

SUBSCRIBE TO OUR NEWSLETTER

Weekly Newsletters About The Latest In Ophthalmic Innovation.

SPONSOR THIS EVENT

Connect and converse with nearly 5,000
innovative ophthalmic professionals.